Company: NGVT
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001653477-25-000127
Chunk: 20

Company: Ingevity Corp
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 20
---
, 2025 and December 31, 2024, respectively.Nonrecurring Fair Value MeasurementsThere were no nonrecurring fair value measurements on the condensed consolidated balance sheets during the periods ended September 30, 2025, and December 31, 2024. Strategic InvestmentsEquity Method InvestmentsThe aggregate carrying value of all strategic equity method investments totaled $15.8 million and $15.4 million at September 30, 2025 and December 31, 2024, respectively. As of September 30, 2025, we had approximately $4.3 million of unfunded commitments associated with a venture capital fund investment accounted for under the equity method of accounting. We anticipate this will be paid over a period of 10 years, beginning from the fourth quarter of 2022. For the three and nine months ended September 30, 2024, the company recognized a gain of zero and $0.1 million related to the sale of an equity method investment, respectively. There were no adjustments to the carrying value of equity method investments for impairment for the periods ended September 30, 2025 and December 31, 2024, respectively. 

10

INGEVITY CORPORATIONNotes to the Condensed Consolidated Financial StatementsSeptember 30, 2025(Unaudited)

Measurement Alternative InvestmentsDuring the third quarter of 2025, strategic investments accounted for under the measurement alternative method increased $20.0 million. The aggregate carrying value of all measurement alternative investments where fair value is not readily determinable totaled $89.4 million and $71.9 million at September 30, 2025 and December 31, 2024, respectively. During the second quarter of 2025 and the third quarter of 2024, the company identified trigger events indicating that certain investments being accounted for under the measurement alternative may be impaired. For the nine months ended September 30, 2025, the company recognized an impairment of $2.5 million, recorded in "Other (income) expense, net" on the condensed consolidated statements of operations. For the three and nine months ended September 30, 2024, the company recognized an impairment of $2.2 million recorded in "Other (income) expense, net" on the condensed consolidated statements of operations.Restricted Investment Our restricted investment is a trust managed in order to secure repayment of the finance lease obligation associated with our Performance Materials' Wickliffe, Kentucky manufacturing site at maturity. The trust, presented as Restricted